Advertisement

Topics

Richard Pzena's Largest -nd-Quarter Buys

16:47 EDT 22 Aug 2017 | Topix

Pzena's Mylan NV stake was increased 69.91% with an impact of 1.08% on the portfolio. The pharmaceutical drug manufacturer develops generic and over-the-counter products in a variety of dosage forms and therapeutic categories.

Original Article: Richard Pzena's Largest -nd-Quarter Buys

NEXT ARTICLE

More From BioPortfolio on "Richard Pzena's Largest -nd-Quarter Buys"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...